Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-ipilimumab uptake and biodistribution imaging in metastatic melanoma during ipilimumab + nivolumab treatment
NL-OMON60044Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab, nivolumab and 89Zr-ipilimumab in melanoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Detection of 89Zr-ipilimumab in tumor lesions. Started Oct 2024; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON60044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60044.